Clarke S D, Woo S Y, Butler E B, Dennis W S, Lu H, Carpenter L S, Chiu J K, Thornby J I, Baskin D S
Department of Radiology, Baylor College of Medicine, Houston, TX 77030.
Radiology. 1993 Sep;188(3):759-63. doi: 10.1148/radiology.188.3.8394591.
A retrospective review of 44 patients with secretory pituitary adenoma treated with radiation therapy (median total dose of 4,500 cGy with a median fraction size of 225 cGy) was performed to analyze response rates and possible variables associated with failure to respond and with complications. The treatment technique used for 75% of the patients was a combination field; an opposed-lateral fields technique was used for the remainder. Median follow-up was 78.5 months, with 59% followed up for more than 60 months and 34% for more than 120 months. Overall survival was 90%, and disease-free survival was 62%. Response rates were 86% for the group with prolactinoma, 67% for the group with acromegaly, and 50% for the group with Cushing disease; the overall response rate was 71%. Findings of suprasellar extension and those from treatment with opposed-lateral fields correlated significantly with failure to respond. A higher percentage of patients with invasive macroadenomas also failed to respond. More complications were found in patients treated with opposed-lateral fields, but the numbers were too small to reach significance. Radiation therapy remains an important adjunct for the treatment of many patients with secretory pituitary adenoma.
对44例接受放射治疗的分泌性垂体腺瘤患者进行了回顾性研究(中位总剂量为4500 cGy,中位分次剂量为225 cGy),以分析缓解率以及与无反应和并发症相关的可能变量。75%的患者使用的治疗技术是联合野;其余患者使用对侧野技术。中位随访时间为78.5个月,59%的患者随访时间超过60个月,34%的患者随访时间超过120个月。总生存率为90%,无病生存率为62%。泌乳素瘤组的缓解率为86%,肢端肥大症组为67%,库欣病组为50%;总体缓解率为71%。鞍上扩展的发现以及对侧野治疗的发现与无反应显著相关。侵袭性大腺瘤患者无反应的比例更高。对侧野治疗的患者出现更多并发症,但数量太少,未达到显著水平。放射治疗仍然是许多分泌性垂体腺瘤患者治疗的重要辅助手段。